Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for prevention of liver fibrosis in non-alcoholic fatty liver disease
IRCT20170609034406N12Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of allopurinol in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis, sponsored by Tabriz University of Medical Sciences. Primary endpoints: hs-CRP, MDA and 2 more. Started Nov 2024; status: completed.
02
Drugs
allopurinol
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosis
Beyond the preview
Go deeper on IRCT20170609034406N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170609034406N12.